Table 1. Baseline patient characteristics.
| Variables | Patients (n=60) |
|---|---|
| Age | |
| ≤60 | 40 (66.7%) |
| >60 | 20 (33.3%) |
| Sex | |
| Male | 51 (85.0%) |
| Female | 9 (15.0%) |
| Aetiology | |
| HBV | 58 (96.7%) |
| Non-HBV non-HCV | 2 (3.3%) |
| Child-Pugh class | |
| A | 54 (90.0%) |
| B | 6 (10.0%) |
| HBV-DNA, IU/mL | |
| ≥1,000 | 11 (18.3%) |
| <1,000 | 49(81.7%) |
| AFP, ng/mL | |
| ≥400 | 33 (55.0%) |
| <400 | 27 (45.0%) |
| BCLC stage | |
| B | 17 (28.3%) |
| C | 43 (71.7%) |
| Disease sites | |
| Liver | 51 (85.0%) |
| Liver without macrovascular invasion | 25 (41.7%) |
| Liver with major vascular invasion | 26 (43.3%) |
| Lung | 11 (18.3%) |
| Lymph nodes | 10 (16.7%) |
| Intra-abdomen | 8 (13.3%) |
| Bone | 4 (6.7%) |
| Brain | 1 (1.7%) |
| Combination strategies | |
| Sintilimab +Lenvatinib | 48 (80.0%) |
| Sintilimab + Sorafenib | 3 (5.0%) |
| Sintilimab + Regorafenib | 4 (6.7%) |
| Sintilimab + Apatinib | 5 (8.3%) |
| Combination therapy as systemic | |
| First-line | 44 (73.3%) |
| Second-line | 9 (15.0%) |
| Third-line | 6 (10.0%) |
| Fourth-line | 1 (1.7%) |
HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, alpha fetal protein; BCLC, Barcelona Clinic Liver Cancer.